Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7346877 | 0.85 | GPR139 (0.41) | GPR139EPHX2TP53 | |
| SCHEMBL7839115 | 0.83 | GPR139 (0.38) | GPR139EPHX2TP53 | |
| SCHEMBL7339448 | 0.82 | GPR139 (0.40) | GPR139EPHX2KDM4ETP53 | |
| SCHEMBL7339157 | 0.80 | TACR1 (0.44) | GPR139RAB9ANPC1MAPTEPHX2 | |
| SCHEMBL7341105 | 0.80 | CTSL (0.46) | GPR139CYP1A2TP53 | |
| SCHEMBL7834975 | 0.80 | EGFR (0.37) | GPR139MAPTHPGDTP53 | |
| SCHEMBL6774582 | 0.79 | ITGB3 (0.43) | GPR139 | |
| SCHEMBL7341748 | 0.78 | TACR1 (0.41) | GPR139TP53 | |
| SCHEMBL7836793 | 0.77 | GPR139 (0.38) | GPR139 | |
| SCHEMBL7344119 | 0.77 | GPR139 (0.38) | GPR139MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831199-B1 | In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 | G. D. SEARLE & CO. | 2004-12-14 | — | — | US | disclosed |
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |